UBS analyst Joshua Spector upgraded Chemours to Buy from Neutral with a price target of $43, up from $31. UBS believes TiO2 earnings will recover through 2023 from current trough levels, with focus shifting to sustainability-led growth in non-TiO2 segments, driving EBITDA toward record highs in the firm’s outlook and lifting Chemours’s multiple, the analyst tells investors in a research note.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CC:
